Autologous Tumor Infiltrating Lymphocytes LM103 clinical trials
Also written LM103.
Its developmentBy Suzhou BlueHorse Therapeutics, step by step7 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Autologous Tumor Infiltrating Lymphocytes LM103 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous Tumor Infiltrating Lymphocytes LM103 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Suzhou BlueHorse Therapeutics Co., Ltd. (7)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Autologous Tumor Infiltrating Lymphocytes LM103 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase II Trial of LM103 in Advanced MelanomaRecruitingPhase 2Suzhou BlueHorse Therapeutics Co., Ltd.NCT07310784Written as LM103 TILs Injection
- A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung CancerRecruitingPhase 2Suzhou BlueHorse Therapeutics Co., Ltd.NCT07444437Written as LM103 TILs Injection
- An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid TumoursRecruitingEarly Phase 1Suzhou BlueHorse Therapeutics Co., Ltd.NCT06697665Written as LM103
- A Clinical Study on TILs for the Treatment of Advanced Solid TumorsNot yet recruitingEarly Phase 1Suzhou BlueHorse Therapeutics Co., Ltd.NCT05971576Written as LM103
- A Clinical Study on LM103 Injection for the Treatment of Advanced Solid TumorsNot yet recruitingEarly Phase 1Suzhou BlueHorse Therapeutics Co., Ltd.NCT05971589Written as LM103
- A Clinical Study on LM103 for the Treatment of Advanced Solid TumorsRecruitingEarly Phase 1Suzhou BlueHorse Therapeutics Co., Ltd.NCT05941936Written as LM103
- A Clinical Study of LM103 Injection in the Treatment of Advanced Solid TumorsRecruitingPhase 1Suzhou BlueHorse Therapeutics Co., Ltd.NCT05366478Written as Autologous tumor infiltrating lymphocytes (TILs)